| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Evommune, Inc.$13.21
-0.3 (-2.22%)
C 49Pipeline Score Undervalued Pharma · Commercial
Market Cap
823.74 M
EPS
-2.39
P/E Ratio
-
Value Trade
5.39 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
17.32 M
Operating CF
-27.50 M
Total Assets
322.45 M
Total Liabilities
17.90 M
Equity
304.56 M
D/E Ratio
12,345
3.06 %
Week
-18.76 %
1 Month
-20.03 %
3 Month
26.84 %
6 Month
32.58 %
5 Year
32.58 %
All Time
Cash Data
Cash Position
211.46 M
Monthly Burn
9.17 M
Runway
20.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
585.87 K
52 Week Range
13.89 - 33.20
% held by Insiders
46.47 %
% held by Institutions
60.12 %
Enterprise Value
621.39 M
Total Shares
36.04 M
Short %
20.65 %
Float Shares
23.14 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Evommune, Inc.
1Total events
0Upcoming
1Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
Jun 29, 2026
◆Topline ReadoutEVO756Clinical Data
Top-line results from EVO756 Phase 2b trial in moderate-to-severe chronic spontaneous urticaria
moderate-to-severe chronic spontaneous urticariasource ↗
Drug Pipeline Intelligence
C49
Pipeline Score $1.1B
Pipeline ValueUndervalued
Valuation Signal3
Drugs Scored4.3x
rNPV / MCap Top 73%
Micro Cap (rank 247 of 912)
Percentile RankEvommune, Inc. carries a moderate pipeline score (49/100), with $3.5B risk-adjusted pipeline value, led by EVO756 in Chronic Spontaneous Urticaria (Phase 2), across $53B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EVO756 Small molecule | Chronic Spontaneous Urticaria | Phase 2 | NCT06873516 | 17% | $2.1B | COMPLETED | 182 | FAST | B (72) | Jun 5, 2026 | LOW_RISK | HIGH Jul 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
EVO756 | moderate-to-severe chronic spontaneous urticaria | Phase 2b | 2026-06-29 | The study did not meet the primary endpoint at any dose. | Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria Read More | |
EVO756 | moderate-to-severe chronic spontaneous urticaria | Phase 2b | 2026-06-29 | The study did not meet the primary endpoint at any dose. | Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria Read More | |
EVO756 | moderate-to-severe chronic spontaneous urticaria | Phase 2b | 2026-06-29 | The study did not meet the primary endpoint at any dose. | Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EVMN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EVMN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
EVMN▼ -40.2%on this news
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
Evommune has announced the top-line results from its EVO756 Phase 2b trial targeting moderate-to-severe chronic spontaneous urticaria. The trial's outcomes are currently being analyzed, but specific details about the results have not been disclosed in the article. Further information may be expected as the company continues its evaluation.
Read more →EVMN▼ -5.6%on this news
Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights
Evommune has reported its financial results for the first quarter of 2026, along with key business highlights. However, the article does not provide specific details about the financial performance or business developments. The lack of information limits the analysis of the company's current standing.
Read more →EVMN▲ +5.9%on this news
Role of MRGPRX2 in Migraine
Evommune, Inc. is advancing its understanding of the role of MRGPRX2 in treating migraines, with its compound EVO756 currently in development for migraine therapy. The company is preparing for a Phase 2b trial to evaluate EVO756's efficacy, supported by promising preclinical data. High patient demand for effective preventative treatments highlights the market potential for EVO756, despite the inherent risks associated with clinical trials and forward-looking statements. The upcoming trial is crucial for assessing the compound's therapeutic benefits in a field with significant unmet needs.
Read more →EVMNEvommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine
Evommune is set to host a Key Opinion Leader (KOL) webinar on April 13, 2026. The focus of the webinar will be on the potential of MRGPRX2 inhibition in treating migraines. This event aims to provide insights into the therapeutic prospects of this approach.
Read more →EVMN▲ +6.4%on this news
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights – Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD
Evommune, Inc. reported positive financial results for the fourth quarter and full year 2025, including encouraging top-line data from the Phase 2a trial of EVO301 for atopic dermatitis. The company successfully raised $125 million through a private placement to enhance its cash position and extend its financial runway until 2028. Evommune is advancing its drug development pipeline, with top-line data from ongoing trials expected in 2026. However, the company faces challenges with a significant net loss, indicating the need for sustainable operations as it progresses in clinical trials.
Read more →EVMNEvommune Announces $125 Million Private Placement Palo Alto, CA., and New York, NY.
Evommune, a clinical-stage biotechnology company, announced a private placement to sell 4,494,279 shares of its common stock for approximately $125 million. The shared price is set at $27.88 each, and the transaction is expected to close around February 17, 2026. The company plans to use the proceeds to advance its clinical development programs and for general corporate purposes. Note that these securities have not been registered under the Securities Act, limiting their immediate sale in certain jurisdictions.
Read more →EVMN▲ +70.9%on this news· ran to +86% by day 3shared move
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Evommune, Inc. announced positive top-line results from its Phase 2a trial of EVO301 for moderate-to-severe atopic dermatitis. The trial demonstrated significant efficacy with a notable percentage of patients achieving improved scores. The company plans to advance to a Phase 2b trial to optimize dosing and enhance patient outcomes. Full results will be presented at a future scientific conference.
Read more →EVMNEvommune Reports Third Quarter 2025 Financial Results and Provides Business Update - Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneo
Evommune, Inc. reported its financial results for the third quarter of 2025, disclosing a net loss of $12.5 million. Following the successful completion of its IPO, which raised $172.5 million, the company is well-positioned to advance its lead programs, EVO756 and EVO301, with three Phase 2 data readouts anticipated in 2026. Notably, EVO756 is showing early positive results in treating chronic spontaneous urticaria, while EVO301 is expected to offer more effective treatment for atopic dermatitis. The company continues to explore additional indications for both candidates.
Read more →Competitive Position
How EVMN ranks across every disease it competes inCompetitive Position is a premium feature
See how EVMN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial